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Design and Engineering of Trastuzumab emtansine production plant
Part I: Introduction to T-DM1 production process and Upstream of monoclonal antibody Trastuzumab
INTRODUCTION
BLOCK DIAGRAM
Figure1. Extracted from PEDDI, Parvin F.; HURVITZ, Sara A. Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncology, 2013, vol. 9, no 3, p. 319-326
1. BAROK, Mark; JOENSUU, Heikki; ISOLA, Jorma. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast cancer research, 2014, vol. 16, no 2, p. 209.
2. LI, Feng, et al. Cell culture processes for monoclonal antibody production. In: MAbs. Taylor & Francis, 2010. p. 466-479.
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Antibody Drug Conjugates (ADC) are potent biopharmaceutical drugs that combine the selectivity of targeted treatments
with the cytotoxic potency of chemotherapy drugs. In this case we design the production plant of Trastuzumab emtansine
for the treatment of breast cancer HER2+ cells. This ADC is composed by:
A highly selective monoclonal antibody (mAb) for a tumour-associated antigen  TRASTUZUMAB
A potent cytotoxic agent designed to induce mitotic arrest DM1
A LINKER stable in circulation that releases the cytotoxic agent in target cells  
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The objective is to treat the population from Europe and USA. Every year 6.25 × 105 new cases are 
diagnosed, from which the 25% that overexpress HER2 receptor can be treated with this therapy.
An average of 3.5 DM1 molecules are bound to 1 molecule of Trastuzumab. 
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Maintaining consistent and comparable product quality is a challenge throughout all the
production process.
In order to screen and select the stable clone with higher productivity and best attributes,
different analytical assays and quality assessment criteria are employed to test antibody
molecular properties.
ELISA and flux cytometry  12-24 best candidates.
Fermentation in shake flasks  4-6 best candidates.
Small-scale bioreactors  definitive clone.
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Human Epidermal Growth Factor Receptor
(HER2) is overexpressed on the surface of
cancer cells and receives signals that
stimulate its growth and proliferation.
T-DM1 binds specifically to HER2 receptor.
The complex is then endocyted into
lysosome where the antibody is degraded to
aminoacids level releasing the Lys-Linker-
DM1 complex.
This complex inhibits microtubule assembly,
eventually causing cell death.
T-DM1 can be broken down inside tumour
cells, but is stable enough not to release the
drug into circulation.
1 Able to fold and secrete immunoglobulines.
2 Glycosylation pattern similar to humans.
3 Adaptable to growing in suspension culture.
4 Adaptable to growing in chemically defined and serum-free
media.
CHO-DG44
Deficient in DHFR  used as selection 
marker
BIOCATALYST: Why CHO cells? VECTOR CONSTRUCTION:
TRICISTRONIC VECTOR
•Simultaneous expression of multiple genes from a single transcript.  
•Same gene expression ratio.
•Reduces non-expressing clones.
•Allows faster and better stable clone selection.
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• The inoculum cell density of all seed train
steps was 0.2 × 106 cells/mL..
• For animal cells, the transfer volume
needs to be minimum 10% of the
following equipment and each step has a
duration of 3 days.
Total time = 15 days
0.5L
1L
10L
50L
500L
2000L
polyA
LC
pcDNA3.1 pcDNA3.1
IRES
PCR overlap
Fermentation
Fermentation
Breast cancer is the most common cancer among women following skin cancer. Specifically, HER2 overexpressing tumours reveal a particularly poor prognosis. For this reason, the aim of this project is to simulate an industrial plant for the
production of the antibody drug conjugate Trastuzumab emtansine (T-DM1) which has resulted to be a successful therapy for this type of breast cancer. T-DM1 is composed by a monoclonal antibody (Trastuzumab) produced in CHO DG44
cells and a cytotoxic drug (DM1) produced in Actinosynnema pretiosum. Therefore, two parallel processes have been designed to produce these two components followed by a mixing step. All simulations have been done using SuperPro
Designer®. This part is focused on the T-DM1’s mechanism of action, the annual amount production of the plant, the block diagram and the upstream process of Trastuzumab which includes the genetic engineering as well as the clone
selection and the scale-up.
ABSTRACT
Figure 1. T-DM1 mechanism of action. 
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Components:
• Light chain (LC)
• Heavy chain (HC)
• Internal Ribosome Entry Site (IRES)
• Dihydrofolate reductase (DHFR)
• Polyadenylation (polyA tail)
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